Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 4/20 | 0.49 |
| ▸ | PYGB | P11216 | 1/20 | 0.48 |
| ▸ | IGF2R | P11717 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.45 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12500139 | 1.00 | LGALS8 (0.49) | LGALS8PYGBIGF2RMAPK1GAA | |
| SCHEMBL24420023 | 0.90 | MAPK1 (0.52) | LGALS8IGF2RMAPK1LGALS3LGALS4 | |
| SCHEMBL15316743 | 0.89 | IGF2R (0.61) | LGALS8PYGBIGF2RMAPK1LGALS3 | |
| SCHEMBL933751 | 0.89 | MAPK1 (0.54) | LGALS8IGF2RMAPK1LGALS3LGALS4 | |
| SCHEMBL9473638 | 0.89 | MAPK1 (0.54) | LGALS8IGF2RMAPK1LGALS3LGALS4 | |
| SCHEMBL8429284 | 0.89 | MAPK1 (0.54) | LGALS8IGF2RMAPK1LGALS3LGALS4 | |
| SCHEMBL8431201 | 0.89 | MAPK1 (0.54) | LGALS8IGF2RMAPK1LGALS3LGALS4 | |
| SCHEMBL8427295 | 0.89 | MAPK1 (0.54) | LGALS8IGF2RMAPK1LGALS3LGALS4 | |
| SCHEMBL8427293 | 0.89 | MAPK1 (0.54) | LGALS8IGF2RMAPK1LGALS3LGALS4 | |
| SCHEMBL15316753 | 0.89 | MAPK1 (0.54) | LGALS8IGF2RMAPK1LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274210-A1 | DENDRIMERS WITH A SACCHARIDE ENDING FOR ANTI-INFLAMMATORY PURPOSES | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2013-10-17 | — | — | US | disclosed |
| US-20130274210-A1 | DENDRIMERS WITH A SACCHARIDE ENDING FOR ANTI-INFLAMMATORY PURPOSES | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274210-A1 | DENDRIMERS WITH A SACCHARIDE ENDING FOR ANTI-INFLAMMATORY PURPOSES | CD44, SELE, CD68 | LGALS8 57/4885PYGB 759/4885IGF2R 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.